Roche scoops up a Treg player for the I/O team, plucking 1 drug and spinning off a 2nd into a new biotech
Roche has snapped up a British biotech which has its own special twist on immuno-oncology — and a couple of key Yank associates in high-profile roles in biotech.
The pharma giant, which has been trying to move ahead in a pack of aggressive PD-1/L1 players with Tecentriq, just paid $81 million (€70 million) upfront and is adding a slate of $679 million more in milestones to grab hold of Tusk Therapeutics — a startup with two late-preclinical programs that are aimed at helping to fashion the next-gen I/O world.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.